Renn Fund Inc  

(Public, NYSEMKT:RCG)   Watch this stock  
Find more results for NYSEAMEX:RCG
-0.01 (-0.86%)
Jun 27 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 1.29 - 1.30
52 week 1.01 - 1.52
Open 1.30
Vol / Avg. 0.00/20,474.00
Mkt cap 5.66M
P/E 4.72
Div/yield     -
EPS 0.27
Shares 4.46M
Beta -0.12
Inst. own 9%

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 47247.75% 13468.07%
Operating margin -7546.85% -8177.90%
EBITD margin - -8177.90%
Return on average assets 56.97% 15.71%
Return on average equity 66.52% 18.11%
CDP Score - -


8080 N Central Expy Ste 210lb59
DALLAS, TX 75206-1838
United States - Map
+1-214-8918294 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


RENN Fund, Inc. (the Fund) is a non-diversified, closed-end management investment company. The investment objective of the Fund is to provide its shareholders primarily with long-term capital appreciation by investing substantially in privately placed convertible and equity securities of emerging growth companies traded on the United States securities exchanges. The Fund seeks to achieve capital appreciation potential by investing in equity securities and convertible issues of small and medium size companies. It invests in various industries, including communication services; surgical and medical instruments and apparatus; telecommunications; crude petroleum and natural gas, and medical chemicals and botanical products. RENN Capital Group, Inc. is the investment advisor of the Fund.

Officers and directors

Russell C. Cleveland Chairman of the Board, President, Chief Executive Officer
Age: 77
Bio & Compensation  - Reuters
Lynne Marie Simon Chief Compliance Officer, Secretary
Bio & Compensation  - Reuters
Ernest C. Hill Independent Director
Age: 77
Bio & Compensation  - Reuters
J. Philip P. McCormick Independent Director
Age: 74
Bio & Compensation  - Reuters
Charles C. Pierce Jr. Independent Director
Age: 81
Bio & Compensation  - Reuters